Effect of Gevilon therapy and its relation to e polymorphism
Németh, A.; Dinya, E.; Audikovszky, M.; Pados, G.; Mannfred, H.
Orvosi Hetilap 135(14): 735-741
1994
ISSN/ISBN: 0030-6002 PMID: 8170672 Document Number: 422839
Our clinical trial was set out to estimate the apoE allele frequency by way of polymerase chain reaction and restriction enzyme isoform genotyping amongst 81 obese, hyperlipoproteinemic patients (treated with gemfibrozil + diet). The relative frequencies of the E2, E3, E4 alleles were 0.28, 0.61, 0.11 respectively (according to the Hardy-Weinberg equilibrium). Phenotypes with increased triglycerides levels were dominant in both sexes: IV + V > II/B > II/A (44.4%, 39.5%, 16.0%). Therapy significantly decreased the atherogen lipid values with differing efficacy among each genotype group: E3 > E4 > E2. Our findings demonstrate that in the II/A group there was no great change using the gemfibrozil + diet combination: whereas in IV + V group this combination was effective in each apoE isoform. In the case of II/B it is highly important to determine the apoE genotypes, because the therapy is only efficacious in the E33 group taking all lipid parameters into consideration.